Søgeresultater - Ramchandren, Radhakrishnan

Advances in the Treatment of Relapsed or Refractory Hodgkin's Lymphoma af Ramchandren, Radhakrishnan

Få fuldtekst Få fuldtekst Få fuldtekst

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia af Ramchandren, Radhakrishnan, Schiffer, Charles A

Få fuldtekst Få fuldtekst

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma af Johnston, Patrick B., Pinter-Brown, Lauren C., Warsi, Ghulam, White, Kristen, Ramchandren, Radhakrishnan

Få fuldtekst Få fuldtekst Få fuldtekst

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study af Goy, Andre, Sinha, Rajni, Williams, Michael E., Kalayoglu Besisik, Sevgi, Drach, Johannes, Ramchandren, Radhakrishnan, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas E.

Få fuldtekst Få fuldtekst Få fuldtekst

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution af SUKARI, AMMAR, NAGASAKA, MISAKO, ALHASAN, ROBA, PATEL, DHAVAL, WOZNIAK, ANTOINETTE, RAMCHANDREN, RADHAKRISHNAN, VAISHAMPAYAN, ULKA, WEISE, AMY, FLAHERTY, LAWRENCE, JANG, HYEJEONG, KIM, SEONGHO, GADGEEL, SHIRISH

Få fuldtekst Få fuldtekst Få fuldtekst

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma af Herrera, Alex F., Goy, Andre, Mehta, Amitkumar, Ramchandren, Radhakrishnan, Pagel, John M., Svoboda, Jakub, Guan, Shanhong, Hill, John S., Kwei, Kevin, Liu, Emily A., Phillips, Tycel

Få fuldtekst Få fuldtekst Få fuldtekst

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment af Zhao, Baiteng, Chen, Robert, O'Connor, Owen A., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Matous, Jeffrey V., Fasanmade, Adedigbo A., Manley, Thomas J., Han, Tae H.

Få fuldtekst Få fuldtekst Få fuldtekst

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL af Goy, Andre, Ramchandren, Radhakrishnan, Ghosh, Nilanjan, Munoz, Javier, Morgan, David S., Dang, Nam H., Knapp, Mark, Delioukina, Maria, Kingsley, Edwin, Ping, Jerry, Beaupre, Darrin M., Neuenburg, Jutta K., Ruan, Jia

Få fuldtekst Få fuldtekst Få fuldtekst

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies af Han, Tae H., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Chen, Robert, Matous, Jeffrey V., Cooper, Maureen, Grove, Laurie E., Alley, Stephen C., Lynch, Carmel M., O’Connor, Owen A.

Få fuldtekst Få fuldtekst Få fuldtekst

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) p... af Goy, Andre, Kalayoglu Besisik, Sevgi, Drach, Johannes, Ramchandren, Radhakrishnan, Robertson, Michael J., Avivi, Irit, Rowe, Jacob M., Herbrecht, Raoul, Van Hoof, Achiel, Zhang, Lei, Cicero, Sherri, Fu, Tommy, Witzig, Thomas

Få fuldtekst Få fuldtekst Få fuldtekst

Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma af Witzig, Thomas E., Zinzani, Pier Luigi, Habermann, Thomas M., Tuscano, Joseph M., Drach, Johannes, Ramchandren, Radhakrishnan, Besisik, Sevgi Kalayoglu, Takeshita, Kenichi, Bravo, Marie-Laure Casadebaig, Zhang, Lei, Fu, Tommy, Goy, Andre

Få fuldtekst Få fuldtekst Få fuldtekst

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation af Gopal, Ajay K., Ramchandren, Radhakrishnan, O'Connor, Owen A., Berryman, Robert B., Advani, Ranjana H., Chen, Robert, Smith, Scott E., Cooper, Maureen, Rothe, Achim, Matous, Jeffrey V., Grove, Laurie E., Zain, Jasmine

Få fuldtekst Få fuldtekst Få fuldtekst

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study af Wang, Michael, Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P., Eliadis, Paul, Peyrade, Frédéric, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K., Tam, Constantine S.

Få fuldtekst Få fuldtekst Få fuldtekst

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies af Bartlett, Nancy L, Chen, Robert, Fanale, Michelle A, Brice, Pauline, Gopal, Ajay, Smith, Scott E, Advani, Ranjana, Matous, Jeffrey V, Ramchandren, Radhakrishnan, Rosenblatt, Joseph D, Huebner, Dirk, Levine, Pamela, Grove, Laurie, Forero-Torres, Andres

Få fuldtekst Få fuldtekst Få fuldtekst

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma af Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L., Rosenblatt, Joseph D., Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M., Fenton, Keenan, Huebner, Dirk, Pinelli, Juan M., Kennedy, Dana A., Shustov, Andrei

Få fuldtekst Få fuldtekst Få fuldtekst

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma af Dang, Nam H., Ogura, Michinori, Castaigne, Sylvie, Fayad, Luis E., Jerkeman, Mats, Radford, John, Pezzutto, Antonio, Bondarenko, Igor, Stewart, Douglas A., Shnaidman, Michael, Sullivan, Sharon, Vandendries, Erik, Tobinai, Kensei, Ramchandren, Radhakrishnan, Hamlin, Paul A., Giné, Eva, Ando, Kiyoshi

Få fuldtekst Få fuldtekst Få fuldtekst

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies af Forero-Torres, Andres, Ramchandren, Radhakrishnan, Yacoub, Abdulraheem, Wertheim, Michael S., Edenfield, William J., Caimi, Paolo, Gutierrez, Martin, Akard, Luke, Escobar, Carolina, Call, Justin, Persky, Daniel, Iyer, Swaminathan, DeMarini, Douglas J., Zhou, Li, Chen, Xuejun, Dawkins, Fitzroy, Phillips, Tycel J.

Få fuldtekst Få fuldtekst Få fuldtekst

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma af Timmerman, John, Herbaux, Charles, Ribrag, Vincent, Zelenetz, Andrew D., Houot, Roch, Neelapu, Sattva S., Logan, Theodore, Lossos, Izidore S., Urba, Walter, Salles, Gilles, Ramchandren, Radhakrishnan, Jacobson, Caron, Godwin, John, Carpio, Cecilia, Lathers, Deanne, Liu, Yali, Neely, Jaclyn, Suryawanshi, Satyendra, Koguchi, Yoshinobu, Levy, Ronald

Få fuldtekst Få fuldtekst Få fuldtekst

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma af Herrera, Alex F., Moskowitz, Alison J., Bartlett, Nancy L., Vose, Julie M., Ramchandren, Radhakrishnan, Feldman, Tatyana A., LaCasce, Ann S., Ansell, Stephen M., Moskowitz, Craig H., Fenton, Keenan, Ogden, Carol Anne, Taft, David, Zhang, Qu, Kato, Kazunobu, Campbell, Mary, Advani, Ranjana H.

Få fuldtekst Få fuldtekst Få fuldtekst

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma af Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A., de Oliveira, Jose S. R., Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Özcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Raut, Monika, Saretsky, Todd L., Nahar, Akash, Kuruvilla, John

Få fuldtekst Få fuldtekst Få fuldtekst